Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Zokinvy

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Zokinvy (lonafarnib) is an orally administered farnesyltransferase inhibitor indicated to reduce the risk of mortality in patients with Hutchinson-Gilford Progeria Syndrome (HGPS) and for the treatment of certain processing-deficient progeroid laminopathies with LMNA mutation and progerin or progerin-like protein accumulation. Zokinvy works by inhibiting the farnesylation of progerin, a mutant form of the lamin A protein, thereby reducing its toxic accumulation in the nuclear envelope and mitigating cellular damage. It is the first FDA-approved therapy specifically targeting the underlying molecular cause of HGPS.

    Fact Table

    Formula

    C27H31ClN4O2

    License

    US FDA (2020)

    Bioavailability

    ~75% (estimated)

    Legal status

    Rx-only

    Chemical Name

    Lonafarnib

    Elimination half-life

    ~4–6 hours

    Dosage (Strength)

    50 mg, 75 mg capsules

    Pregnancy

    Not recommended; may cause fetal harm

    Brands

    Zokinvy

    Protein binding

    99%

    PubChem CID

    16005130

    MedlinePlus

    a620042

    ChEBI

    93083

    ATC code

    L04AX09

    DrugBank

    DB06435

    KEGG

    D12053

    Routes of administration

    Oral

    Directions

    Zokinvy should be taken orally twice daily with food. Dosing is based on body surface area (BSA) and should be calculated by the prescribing physician. The medication should be swallowed whole with water and should not be crushed, chewed, or dissolved. If vomiting occurs within 30 minutes of a dose, the dose may be repeated. Close monitoring is necessary to adjust dosing and manage adverse reactions. A gradual dose ramp-up is recommended to minimize gastrointestinal side effects.

    Ingredients

    Active Ingredient: Lonafarnib Inactive Ingredients: Microcrystalline cellulose, mannitol, sodium starch glycolate, magnesium stearate, and a film-coating containing polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.

    Contraindications

    Zokinvy is contraindicated in patients taking strong or moderate CYP3A inhibitors or inducers, or drugs that are OATP1B1 or OATP1B3 substrates due to the risk of serious drug interactions. It is also contraindicated in patients with known hypersensitivity to lonafarnib or any component of the formulation.

    Cautions

    Hepatic toxicity, gastrointestinal effects (including nausea, vomiting, and diarrhea), and electrolyte abnormalities may occur and require monitoring and management. Liver function tests, serum electrolytes, and renal function should be monitored regularly. Avoid use during pregnancy due to potential teratogenic effects. Effective contraception is advised during treatment and for a period following discontinuation. Use caution in patients with hepatic or renal impairment.

    Side Effects

    Common side effects may include:

    • Nausea
    • Vomiting
    • Diarrhea
    • Abdominal pain
    • Fatigue
    • Headache
    • Anorexia
    • Electrolyte imbalances (e.g., hypokalemia, hypophosphatemia)

    Serious adverse events may include QT prolongation, hepatotoxicity, and significant gastrointestinal toxicity requiring dose adjustments or discontinuation.

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14193

  • Product Reviews